Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management.
Medical Device Network on MSN3d
Vivani treats first patient with long-lasting drug implant for weight lossA day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the ...
AstraZeneca announced that the EC green-lighted the new formulation of the once-weekly type-2 diabetes injection, which will be marketed as Bydureon BCise (exenatide 2mg prolonged-release suspension).
Vivani Medical, Inc. (NASDAQ: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing ...
Findings showed MDS-UPDRS OFF medication scores had worsened (increased) by 5.7 points in exenatide-treated patients compared with a 4.5 point increase with placebo. Treatment with once-weekly ...
Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...
AstraZeneca Plc's (NASDAQ:AZN) Bydureon BCise (exenatide 2 mg prolonged-release suspension for injection) is indicated for type-2 diabetes. Novo Nordisk A/S' (NYSE:NVO) semaglutide is approved as ...
n=8), weekly exenatide injections (Bydureon BCise®, n=8), or weekly 1 mg semaglutide injections (Wegovy®, n=8) for a 9-week treatment duration. Changes in weight will be measured. The study is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback